More MS news articles for March 1999

STGI's Cortisol/Anticortisol Concept in Treating Disease to be Aired on Three Cable TV Networks Including CNBC

Wednesday March 3, 7:29 am Eastern Time

LAS VEGAS--(BW HealthWire)--March 3, 1999--Steroidogenesis Inhibitors International today announced that its cortisol/anti-cortisol approach to treating diseases, some of them with no known treatment at the present time, will be featured on a financial talk show on three cable networks including CNBC.

Host Michael Jackson will be interviewing STGI's President, Dr. Alfred Sapse and Executive Vice President, Dr. Janet Greeson on "Investing In America," a sponsored program which will air on CNBC Saturday, March 27, at 2:00 p.m. EST.

The show will present, for the first time to a lay audience, the essence of the Cortisol/Anticortisol Concept developed by Dr. Sapse in 1984. This concept was presented previously only to medical researchers at the World Congresses and Symposiums in Berlin, Tokyo and more recently in Paris, Vancouver and Las Vegas.

Viewers of this TV program will learn the role played by Cortisol, the powerful hormone manufactured by the adrenal gland in causing disease or major symptoms of diseases and the potential therapeutic role of the anticortisol drugs. Dr. Sapse will discuss STGI's anticortisol drug ANTICORT(TM) as the prototype drug in enhancing the effectiveness of presently used drugs treating AIDS, heart attacks, ulcers, hypertension, diabetes and psoriasis as well as its role in alleviating or reducing symptoms due to cortisol in disorders such as cancers, multiple sclerosis (MS), Lou Gehrig's disease (ALS), aging and Alzheimers.

STGI is a pharmaceutical R&D Corporation engaged in the development of anti-cortisol drugs to be used in diseases/conditions associated with elevated levels of the immunosuppressive hormone cortisol. STGI's flagship anti-cortisol drug ANTICORT has been approved by the FDA to be clinically tested in an HIV population -- a condition, often associated with "high cortisol," that is apparently playing a major role in the destruction of the immune system as encountered in HIV+ and AIDS.

This release may include "forward-looking statement" within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1034. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable it can give no assurance that such expectations will prove correct. This is neither an offer to buy or sell a security. For informational purposes only, from sources deemed to be reliable. For more information visit the company's World Wide Web page at

Steroidogenesis Inhibitors Int'l.
Janet Greeson, Ph.D., 702/735-7001
Performance Strategies, Inc.
Richard Brown/Chuck Gordon, 303/471-5943
H.L. Lanzet Inc.
Herbert Lanzet/DeeDee Lanzet, 212/687-0061

Copyright © 1999 Business Wire. All rights reserved.